ATRX and central nervous system cancer: The U3129 and U3034 patient-derived glioma cells used in this study harbor intronic and missense mutations in ATRX (https://www.hgcc.se/, accessed on 21 March 2022), which, besides potential alterations to protein functionality, lead to reduced ATRX levels (Figure S5C,D).